Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1

Journal of General Virology

Volumn 95, Issue PART 1, 2014, Pages 190-200

  Sutherland, Katherine A ^a   Mbisa, Jean L ^a   Cane, Patricia A ^a   Pillay, Deenan ^b   Parry, Chris M ^a,b,c  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; DARUNAVIR; GAG PROTEIN; INDINAVIR; LOPINAVIR; PROTEINASE; PROTEINASE INHIBITOR; SAQUINAVIR; TIPRANAVIR;

AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CASE REPORT; CLONE; CONTROLLED STUDY; DRUG EFFECT; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PRIORITY JOURNAL; REVERTANT; SITE DIRECTED MUTAGENESIS; UNITED KINGDOM; VIRUS MUTANT; VIRUS STRAIN;

EID: 84890281673     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.055624-0     Document Type: Article

References (32)

1. Baxter, J. D., Schapiro, J. M., Boucher, C. A., Kohlbrenner, V. M., Hall, D. B., Scherer, J. R. & Mayers, D. L. (2006). Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 80, 10794-10801.
2. Clavel, F. & Mammano, F. (2010). Role of Gag in HIV resistance to protease inhibitors. Viruses 2, 1411-1426.
3. Condra, J. H., Schleif, W. A., Blahy, O. M., Gabryelski, L. J., Graham, D. J., Quintero, J. C., Rhodes, A., Robbins, H. L., Roth, E. & other authors (1995). In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569-571.
4. Croteau, G., Doyon, L., Thibeault, D., McKercher, G., Pilote, L. & Lamarre, D. (1997). Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 71, 1089-1096.
5. Dam, E., Quercia, R., Glass, B., Descamps, D., Launay, O., Duval, X., Kräusslich, H. G., Hance, A. J., Clavel, F. & ANRS 109 Study Group (2009). Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog 5, e1000345.
6. Dolling, D. I., Dunn, D. T., Sutherland, K. A., Pillay, D., Mbisa, J. L., Parry, C. M., Post, F. A., Sabin, C. A., Cane, P. A. & UK HIV Drug Resistance Database (UKHDRD) and the UK Collaborative HIV Cohort Study (UK CHIC) (2013). Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. J Antimicrob Chemother 68, 2339-2343.
7. Gatanaga, H., Suzuki, Y., Tsang, H., Yoshimura, K., Kavlick, M. F., Nagashima, K., Gorelick, R. J., Mardy, S., Tang, C. & other authors (2002). Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J Biol Chem 277, 5952-5961.
8. Gupta, R., Hill, A., Sawyer, A. W. & Pillay, D. (2008). Emergence of drug resistance in HIV type 1-infected patients after receipt of firstline highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 47, 712-722.
9. Gupta, R. K., Kohli, A., McCormick, A. L., Towers, G. J., Pillay, D. & Parry, C. M. (2010). Full-length HIV-1 Gag determines protease inhibitor susceptibility within in-vitro assays. AIDS 24, 1651-1655.
10. Hertogs, K., de Béthune, M. P., Miller, V., Ivens, T., Schel, P., Van Cauwenberge, A., Van Den Eynde, C., Van Gerwen, V., Azijn, H. & other authors (1998). A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 42, 269-276.
11. Jinnopat, P., Isarangkura-na-ayuthaya, P., Utachee, P., Kitagawa, Y., de Silva, U. C., Siripanyaphinyo, U., Kameoka, Y., Tokunaga, K., Sawanpanyalert, P. & other authors (2009). Impact of amino acid variations in Gag and protease of HIV type 1 CRF01_AE strains on drug susceptibility of virus to protease inhibitors. J Acquir Immune Defic Syndr 52, 320-328.
12. Johnson, M., Grinsztejn, B., Rodriguez, C., Coco, J., DeJesus, E., Lazzarin, A., Lichtenstein, K., Rightmire, A., Sankoh, S. & Wilber, R. (2005). Atazanavir plus ritonavir or saquinavir, and lopinavir/ ritonavir in patients experiencing multiple virological failures. AIDS 19, 685-694.
13. Johnson, V. A., Calvez, V., Günthard, H. F., Paredes, R., Pillay, D., Shafer, R., Wensing, A. M. & Richman, D. D. (2011). 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 19, 156-164.
14. Kameoka, M., Isarangkura-na-Ayuthaya, P., Kameoka, Y., Sapsutthipas, S., Soonthornsata, B., Nakamura, S., Tokunaga, K., Sawanpanyalert, P., Ikuta, K. & Auwanit, W. (2010). The role of lysine residue at amino acid position 165 of human immunodeficiency virus type 1 CRF01_AE Gag in reducing viral drug susceptibility to protease inhibitors. Virology 405, 129-138.
15. Kempf, D. J., Isaacson, J. D., King, M. S., Brun, S. C., Xu, Y., Real, K., Bernstein, B. M., Japour, A. J., Sun, E. & Rode, R. A. (2001). Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 75, 7462-7469.
16. Koyanagi, Y., Miles, S., Mitsuyasu, R. T., Merrill, J. E., Vinters, H. V. & Chen, I. S. (1987). Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236, 819-822.
17. Li, Y., Kappes, J. C., Conway, J. A., Price, R. W., Shaw, G. M. & Hahn, B. H. (1991). Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and-defective viral genomes. J Virol 65, 3973-3985.
18. Lisovsky, I., Schader, S. M., Martinez-Cajas, J. L., Oliveira, M., Moisi, D. & Wainberg, M. A. (2010). HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes. Antimicrob Agents Chemother 54, 2878-2885.
19. London HIV Consortium (2011). Summary of ARV prescribing guidelines in London. http://i-base.info/wp-content/uploads/2011/03/ London-commissioning-2011.pdf
20. Maguire, M. F., Guinea, R., Griffin, P., Macmanus, S., Elston, R. C., Wolfram, J., Richards, N., Hanlon, M. H., Porter, D. J. & other authors (2002). Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J Virol 76, 7398-7406.
21. Marcelin, A. G., Flandre, P., de Mendoza, C., Roquebert, B., Peytavin, G., Valer, L., Wirden, M., Abbas, S., Katlama, C. & other authors (2007). Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients. Antivir Ther 12, 247-252.
22. Molla, A., Korneyeva, M., Gao, Q., Vasavanonda, S., Schipper, P. J., Mo, H. M., Markowitz, M., Chernyavskiy, T., Niu, P. & other authors (1996). Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 2, 760-766.
23. Nijhuis, M., van Maarseveen, N. M., Lastere, S., Schipper, P., Coakley, E., Glass, B., Rovenska, M., de Jong, D., Chappey, C. & other authors (2007). A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 4, e36.
24. Ono, A. & Freed, E. O. (2004). Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body. J Virol 78, 1552-1563.
25. Parry, C. M., Kohli, A., Boinett, C. J., Towers, G. J., McCormick, A. L. & Pillay, D. (2009). Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1. J Virol 83, 9094-9101.
26. Parry, C. M., Kolli, M., Myers, R. E., Cane, P. A., Schiffer, C. & Pillay, D. (2011). Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity. Antimicrob Agents Chemother 55, 1106-1113.
27. Pellegrin, I., Breilh, D., Ragnaud, J. M., Boucher, S., Neau, D., Fleury, H., Schrive, M. H., Saux, M. C., Pellegrin, J. L. & other authors (2006). Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study). Antivir Ther 11, 421-429.
28. Pellegrin, I., Wittkop, L., Joubert, L. M., Neau, D., Bollens, D., Bonarek, M., Girard, P. M., Fleury, H., Winters, B. & other authors (2008). Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study). Antivir Ther 13, 271-279.
29. Petropoulos, C. J., Parkin, N. T., Limoli, K. L., Lie, Y. S., Wrin, T., Huang, W., Tian, H., Smith, D., Winslow, G. A. & other authors (2000). A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 44, 920-928.
30. Vergne, L., Stuyver, L., Van Houtte, M., Butel, C., Delaporte, E. & Peeters, M. (2006). Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. J Clin Virol 36, 43-49.
31. Zennou, V., Mammano, F., Paulous, S., Mathez, D. & Clavel, F. (1998). Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 72, 3300-3306.
32. Zhang, Y. M., Imamichi, H., Imamichi, T., Lane, H. C., Falloon, J., Vasudevachari, M. B. & Salzman, N. P. (1997). Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 71, 6662-6670.